



Original article

Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors

Sherifa Hasabelnaby^{a,b,*}, Ayman Goudah^{b,c}, Hitesh K. Agarwal^b, Mosaad S.M. Abd alla^a, Werner Tjarks^{b,**}

^a Division of Pharmaceutical Organic Chemistry, College of Pharmacy, Helwan University, Ain Helwan, Cairo, Egypt

^b Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, United States

^c Division of Pharmacology, College of Veterinary Medicine, Cairo University, Giza, Egypt

ARTICLE INFO

Article history:

Received 27 April 2012

Received in revised form

5 July 2012

Accepted 18 July 2012

Available online 27 July 2012

Keywords:

3-Carboranyl thymidine analogs

Amino acid ester prodrugs

Boron neutron capture therapy

Glioblastoma multiforme

ABSTRACT

Various water-soluble L-valine-, L-glutamate-, and glycine ester prodrugs of two 3-Carboranyl Thymidine Analogs (3-CTAs), designated N5 and N5-2OH, were synthesized for Boron Neutron Capture Therapy (BNCT) of brain tumors since the water solubilities of the parental compounds proved to be insufficient in preclinical studies. The amino acid ester prodrugs were prepared and stored as hydrochloride salts. The water solubilities of these amino acid ester prodrugs, evaluated in phosphate buffered saline (PBS) at pH 5, pH 6 and pH 7.4, improved 48–6600 times compared with parental N5 and N5-2OH. The stability of the amino acid ester prodrugs was evaluated in PBS at pH 7.4, Bovine serum, and Bovine cerebrospinal fluid (CSF). The rate of the hydrolysis in all three incubation media depended primarily on the amino acid moiety and, to a lesser extent, on the site of esterification at the deoxyribose portion of the 3-CTAs. In general, 3'-amino acid ester prodrugs were less sensitive to chemical and enzymatic hydrolysis than 5'-amino acid ester prodrugs and the stabilities of the latter decreased in the following order: 5'-valine > 5'-glutamate > 5'-glycine. The rate of the hydrolysis of the 5'-amino acid ester prodrugs in Bovine CSF was overall higher than in PBS and somewhat lower than in Bovine serum. Overall, 5'-glutamate ester prodrug of N5 and the 5'-glycine ester prodrugs of N5 and N5-2OH appeared to be the most promising candidates for preclinical BNCT studies.

© 2012 Elsevier Masson SAS. All rights reserved.

1. Introduction

Boron Neutron Capture Therapy (BNCT) is a binary cancer treatment modality that is based on the irradiation of boron-10 (¹⁰B), a stable isotope, with low energy (thermal) neutrons. The resulting capture reaction produces cytotoxic high linear energy transfer (LET) lithium- and helium nuclei (α -particles). These have ranges of <10 μ m in biological tissue, which approximates one cell diameter. Thus, lethal damage caused by BNCT can be restricted largely to cancerous tissue by selective delivery of ¹⁰B to cancer cells. Approximately 20 μ g of ¹⁰B/g tumor and tumor-to-normal tissue ratios larger than 3:1 at the time of neutron irradiation are required for successful BNCT [1].

In recent years, 3-Carboranyl Thymidine Analogs (3-CTAs), such as N5 and N5-2OH, (compounds **1** & **2**, Fig. 1), have been a major focus of compound development for BNCT of high-grade brain tumors, such as glioblastoma multiforme (GBM) [2–5]. Human thymidine kinase 1 (hTK1), an enzyme of the DNA salvage pathway synthesis that is predominantly active in proliferating cells [6],

Abbreviations: ¹⁰B, boron-10; 3-CTAs, 3-carboranyl thymidine analogs; AUCs, areas under the curves; BNCT, boron neutron capture therapy; Boc, butoxycarbonyl; BSA, Bovine serum albumin; BuLi, butyllithium; CSF, cerebrospinal fluid; DCC, dicyclohexylcarbodiimide; DCM, dichloromethane; DMAP, 4-dimethylaminopyridine; DMF, dimethyl formamide; DMSO, dimethyl sulfoxide; GBM, glioblastoma multiforme; HR-ESI, high resolution-electrospray ionization; hTK1, human thymidine kinase 1; ISF, interstitial fluid; i.c., intracranial; i.t., intratumoral; i.v., intravenous; KMT, kinase mediated trapping; LET, linear energy transfer; OSU-CCIC, The Ohio State University Campus Chemical Instrumentation Center; PBS, phosphate buffered saline; RP-18, reversed phase 18; rt, room temperature; TBAF, tetrabutylammonium fluoride; TBDMS, *tert*-butyldimethylsilyl; TFA, trifluoroacetic acid; Thd, thymidine; THF, tetrahydrofuran; TK1, thymidine kinase 1.

* Corresponding author. Division of Pharmaceutical Organic Chemistry, College of Pharmacy, Helwan University, Ain Helwan, Cairo, Egypt.

** Corresponding author. Tel./fax: +1 614 292 7624.

E-mail addresses: sherifajanaa@yahoo.com (S. Hasabelnaby), tjarks.1@osu.edu (W. Tjarks).




Fig. 1. Structures of N5 (1), N5-2OH (2), acyclovir (3), and valacyclovir (4).

catalyzes the 5'-monophosphorylation of these agents. Apparently, this causes the selective accumulation of 3-CTAs in cancer cells by a process that has been referred to as Kinase Mediated Trapping (KMT) [5,7]. The *in vitro* uptake of **1** and **2** in TK1 (+) L929 cells was 5–10 higher than in TK1 (–) L929 cells following 24 h incubation in compound containing medium. In addition, both compounds were retained only in the former cell line when incubation was continued for 12 h in compound free medium [2]. After intratumoral (i.t.) injection of **2** into subcutaneous TK1 (+)– or TK1 (–) L929 tumors implanted in nude mice, boron concentrations were ~3 times higher in the former tumor [3]. Survival times of rats bearing intracranial RG2 glioma that had received **2** via intracranial (i.c.) injection prior to BNCT were about 2 times longer compared with rats that received BNCT without administration of **2** [3]. Compared with i.c. and i.t. injections, intravenous (i.v.) administration of **2** appeared to be less effective [3].

These biological studies clearly established the therapeutic potential of **1** and **2** but they also revealed a major limitation. Both compounds are very lipophilic because of the presence of the carborane cluster [4] and the absence of any functional groups that can be ionized under physiological conditions. Thus, both agents are almost insoluble in water and aqueous solutions containing 30–70% dimethyl sulfoxide (DMSO) had to be used to solubilize **2** for i.t. and i.c. injections into tumor-bearing rodents [3]. Although no significant pathologic alterations were observed in rat brains following i.c. injections [3], administration of **2** in DMSO via i.c. route to the brain of human patients with intracranial tumors has the potential to cause damage to healthy brain tissue. Even if such injections should prove to be acceptable for humans, it may significantly complicate approval of clinical trials by regulatory agencies.

A successful approach to overcome water-insolubility of drugs has been the preparation of carrier-linked prodrugs [8]. For the design and synthesis of water-soluble amino acid ester prodrugs of **1** and **2**, three important factors have to be considered: 1) The water solubilities of the amino acid ester prodrugs of **1** and **2** should be in the range of those of the parental compounds in aqueous DMSO solutions. 2) The tumor selective uptake of **1** and **2** depends on TK1 depended KMT. Thus, cleavage of any promoiety attached to **1** and **2** should be rapid, as additional structural modification of these structures, not only at the 5'-position, will most likely abolish their TK1 substrate characteristics [9]. 3) The protein (enzyme)

concentration in the interstitial fluid (ISF) of the brain appears to be significantly lower than that in normal serum [10]. The increased molecular weight and hydrophilicity of prodrugs of **1** and **2** may prevent their effective passage through cell membranes and the subsequent intracellular enzymatic removal of the promoiety. Therefore, cleavage of such prodrugs following i.c. administration may depend primarily on chemical rather than enzymatic hydrolysis in brain ISF.

Consequently, the ideal water-solubilizing promoieties for **1** and **2** should be rapidly cleavable by chemical hydrolysis. Phosphate-, carbohydrate-, or sulfate esters are probably not suitable as promoieties of **1** and **2** because they proved to be sensitive to enzymatic cleavage but were fairly resistant toward chemical hydrolysis when used for other types of agents [11–13]. In contrast, amino acid ester prodrugs of established drugs, such as the antibiotic/antiprotozoal metronidazole [14], the anticancer nucleoside analogues gemcitabine, floxuridine and cytarabine [15–18], and the widely used antiviral nucleoside analog acyclovir [19,20] (compound **3**, Fig. 1) proved to be sensitive to both enzymatic and chemical hydrolysis. In addition, valacyclovir (compound **4**, Fig. 1), the established valine ester prodrug of acyclovir, is about 130 times better water-soluble than its parental nucleoside analog [21].


This paper describes the design, synthesis, and evaluation of water-soluble amino acid ester prodrugs of **1** and **2**. Based on the aforementioned studies with metronidazole, gemcitabine, floxuridine, cytarabine, and acyclovir, glycine-, L-valine-, and L-glutamate were selected as promoieties. The chemical and enzymatic stabilities of the synthesized amino acid ester prodrugs were evaluated in phosphate buffered saline (PBS), Bovine serum, and Bovine cerebrospinal fluid (CSF), which has a similar protein concentration as brain ISF [10]. The solubilities of the synthesized prodrugs were evaluated in PBS at pH 5, pH 6, and pH 7.4.

2. Results and discussion


2.1. Chemistry

The syntheses of N5 (**1**) and acetone-protected N5-2OH (**10**) are shown in Schemes 1 and 2. Both compounds served as starting materials in the synthesis of the amino acid ester prodrugs of **1** and N5-2OH (**2**), as shown in Scheme 3.

Previously reported syntheses for **1** utilized highly toxic and explosive decaborane as the starting material [22,23]. Therefore, an alternative synthesis was developed, which is shown in Scheme 1. In this route, *tert*-butyldimethylsilyl (TBDMS)-*o*-carborane (**5**) is



Scheme 1. Reagents and conditions: (a) *n*-BuLi, THF, 1,5-pentandiol ditosylate, 5 h, 80 °C; (b) Thd, K₂CO₃, DMF/acetone (1/1), 6 h, 50 °C; (c) TBAF, THF, 0.5 h, rt.



Scheme 2. Reagents and conditions: (a) *n*-BuLi, THF, 1,5-diiodopentane, 6 h, 80 °C; (b) Thd, K₂CO₃, DMF/acetone (1/1), overnight, 50 °C.


used as the starting material, which is prepared from less toxic, stable, and commercially-available *o*-carborane [24]. The reaction of **5** with *n*-BuLi in THF followed by addition of 1,5-pentandiol ditosylate [25] afforded compound **6** in 36% yield. Use of readily available commercial 1,5-diiodopentane rather than 1,5-pentandiol ditosylate resulted in complex reaction mixtures from which the desired product could not be separated effectively. Reacting **6** with thymidine (Thd) in the presence of potassium carbonate in a DMF/acetone (1/1) mixture at 50 °C gave compound **7** in 65% yield. Removal of the TBDMS protective group of compound **7** was achieved with tetrabutylammonium fluoride (TBAF) in THF at room temperature for 0.5 h to give target compound **1** in 58% yield.

Compound **10** was prepared according to Scheme 2. In this reaction sequence, treatment of compound **8** [25] with *n*-BuLi followed by addition of 1,5-diiodopentane rather than 1,5-pentandiol

ditosylate, as described previously by Byun et al. [25], was feasible yielding **9** in 41% yield. The reaction of **9** with Thd in the presence of potassium carbonate in a DMF/acetone mixture at 50 °C produced **10** in 48% yield.

Compound **1** was treated with commercially available *N*-Boc protected amino acids (*N*-Boc-L-valine, *N*-Boc-glycine, or *N*-Boc-L-glutamic acid α -*tert*-butyl ester). As reported by Anand et al. [19] and Katragadda et al. [20] for studies with acyclovir, glutamic acid was attached to the 5'-position of **1** via the γ -carboxylic function. For reasons discussed in section 2.2, compound **10** was only treated with *N*-Boc-glycine. All reactions were carried out in the presence of dicyclohexylcarbodiimide (DCC) and a catalytic amount of 4-dimethylaminopyridine (DMAP) in DMF for 24 h at room temperature to give mixtures of 3'-*N*-Boc-, 5'-*N*-Boc-, and 3',5'-di-*N*-Boc-amino acid ester prodrugs of **1** and **10** (Scheme 3). Progress of the reactions was monitored by TLC and separation of the Boc-protected amino acid ester prodrugs was possible by column chromatography. Unfortunately, all of these isolated intermediates remained contaminated with DCC (see supplementary material for ¹H NMR data and *R*_f values). Thus, removal of the Boc groups from these partially purified intermediates was achieved with a 50% solution of trifluoroacetic acid (TFA) in dichloromethane at room temperature for 2 h to give the 3'-monosubstituted amino acid ester prodrugs **11**, **14**, **17**, and **20** (Scheme 3) in yields ranging from 1% to 5%, the 5'-monosubstituted amino acid ester prodrugs **12**, **15**, **18**, and **21** (Scheme 3) in yields ranging from 7% to 22%, and the 3',5'-disubstituted amino acid ester prodrugs **13**, **16**, **19**, and **22** (Scheme 3) in yields ranging from 13% to 30%.

In the case of the glutamate ester prodrugs of **5** (**17–19**), the reaction was carried for 4 h to assure removal of both the Boc- and the α -*tert*-butyl protective group. All amino acid ester prodrugs were obtained with wax-like consistency following purification by preparative RP18-HPLC (Table 3) and were analyzed and identified by ¹H NMR, ¹³C NMR, and MS. The latter method was most useful to



Scheme 3. Reagents and conditions: (a) *N*-Boc-L-amino acids, DCC, DMAP, 24 h, rt; (b) Partial column chromatographic purification (ethyl acetate/hexanes, 8/5) of 3'-*N*-Boc-, 5'-*N*-Boc-, and 3',5'-di-*N*-Boc-amino acid esters of **1** and **10**; (c) TFA:DCM, 1:1, 2 h – 4 h, rt; (d) 1 M HCl in diethyl ether, THF, overnight, rt.

Table 1
Prodrug half-lives ($t_{1/2}$) in PBS (pH 7.4), Bovine serum, and Bovine CSF.

Compds	$t_{1/2}$ (h)		
	PBS	Bovine serum	Bovine CSF
4	13.60 ± 0.49	6.20 ± 0.17	7.59 ± 0.12
11	29.79 ± 0.42	ND	ND
12	25.59 ± 0.61	22.21 ± 0.52	25.47 ± 0.10
13	12.91 ± 0.17	ND	ND
14	1.51 ± 0.11	ND	ND
15	0.70 ± 0.04	0.69 ± 0.02	0.96 ± 0.04
16	0.22 ± 0.03	ND	ND
17	26.91 ± 0.71	ND	ND
18	11.16 ± 0.37	0.85 ± 0.12	1.85 ± 0.11
19	3.42 ± 0.10	ND	ND
21	2.21 ± 0.15	1.51 ± 0.04	2.11 ± 0.14

Standard deviations are based on three experiments; ND = not determined.

distinguish between monosubstituted- and disubstituted amino acid ester prodrugs, whereas ^1H NMR spectroscopy was helpful to distinguish between 3'-monosubstituted- and 5'-monosubstituted amino acid ester prodrugs based on the chemical shifts (δ) of the 3'- and 5'-protons. In general, amino acid ester substitution at the 3'-hydroxyl group caused a downfield shift for the signal of the 3'-Hs from 3.88 ppm and 3.95 ppm in the case of **1** and **10**, respectively, to 5.04 ppm–5.54 ppm in the case of **11**, **14**, **17**, and **20** whereas 5'-substitution caused a downfield shift for the signal of the 5'-Hs from 3.74 ppm and 3.81 ppm in the case of **1** and **10**, respectively, to 4.30 ppm – 4.74 ppm in the case of **12**, **15**, **18**, and **21**.

The low overall yields starting from **1** or **10** are a shortcoming of the applied synthetic route. However, low yields are inherent to this specific synthetic route and have also been reported previously in the synthesis of various gemcitabine amino acid ester prodrugs [15]. On the other hand, introduction of ester functions at different hydroxyl groups is desirable to explore which ester site is most susceptible to chemical or enzymatic cleavage (see section 2.2). Once the optimal esterification site has been identified, appropriate protective group strategies could be applied to improve yields.

Treatment of **11–22** (Scheme 3) with commercially available anhydrous 1 M HCl gas in diethyl ether followed by stirring overnight at room temperature gave the corresponding hydrochloride salts **11•HCl–22•HCl** (Scheme 3) in yields ranging from 50% to 70%. The formation of **11•HCl–22•HCl** was confirmed by elemental analysis except for the 3'-glycine ester prodrug of N5 (**14**) since the low synthetic yield for this compound limited its availability.

These hydrochloride salts were synthesized for two reasons. 1) They had crystalline consistency and were much easier to handle than the wax-like free bases. 2) Various amino acid ester prodrugs of acyclovir (**3**), AZT, and gemcitabine exhibited significant stability

Table 2
pKa values and compound solubilities in PBS at pH 5, pH 6, and pH 7.4 at 37 °C.

Compds	pKa Values ^a	PBS pH 5	PBS pH 6	PBS pH 7.4
1	–	0.003–0.005 g/L	0.003–0.005 g/L	0.003–0.005 g/L
2	–	0.007–0.01 g/L	0.007–0.01 g/L	0.007–0.01 g/L
4	1.90, 7.47 & 9.43 ^b	72.70 ± 0.40 g/L	13.43 ± 0.26 g/L	1.91 ± 0.06 g/L
12	~7.85	26.30 ± 0.90 g/L	3.70 ± 0.31 g/L	1.31 ± 0.05 g/L
15	~7.30	10.99 ± 0.20 g/L	2.06 ± 0.11 g/L	0.19 ± 0.01 g/L
18	~2.20 & ~9.25	1.16 ± 0.04 g/L	1.13 ± 0.06 g/L	1.77 ± 0.08 g/L
21	~7.30	11.18 ± 0.21 g/L	3.60 ± 0.12 g/L	0.62 ± 0.03 g/L

Standard deviations are based on three experiments.

^a The pKa values for **12**, **15**, **18**, and **21** are estimated based on calculations using Advanced Chemistry Development (ACD/Labs) software within ScifinderScholar[®] for the corresponding benzyl esters.

^b Measured values from reference [36].

Table 3
HPLC methods and retention times of compounds **1–4** and **11–22**.

Compds	Method ^a	Retention time (min)		
		3'	5'	3', 5'
11–13	A1 –65:35 to 30:70 (H ₂ O:MeCN) over 27 min	18.82	18.09	13.91
14–16	A2 –70:30 to 30:70 (H ₂ O:MeCN) over 27 min	18.43	17.57	14.67
17–19	A3 –60:40 to 30:70 (H ₂ O:MeCN) over 27 min	13.99	13.69	8.92
20–22	A2 –70:30 to 30:70 (H ₂ O:MeCN) over 27 min	14.00	13.51	10.55
11–13	B1 –65:35 to 0:100 (H ₂ O:MeOH) over 40 min	33.03	31.29	27.63
14–16	B2 –70:30 to 0:100 (H ₂ O:MeOH) over 40 min	30.61	30.40	26.45
17–19	B3 –60:40 to 0:100 (H ₂ O:MeOH) over 40 min	32.05	31.64	26.50
20–22	B2 –70:30 to 0:100 (H ₂ O:MeOH) over 40 min	28.30	28.18	23.52
		Retention time (min)		
1	A1 –65:35 to 30:70 (H ₂ O:MeCN) over 27 min	25.45		
2	A2 –70:30 to 30:70 (H ₂ O:MeCN) over 27 min	18.72		
3	A4 –100:0 to 85:15 (H ₂ O:MeCN) over 20 min	14.35		
4	A4 –100:0 to 85:15 (H ₂ O:MeCN) over 20 min	19.43		

^a Solvent systems contained 0.1% TFA.

in aqueous solution in the pH-range of 3–5 for several days whereas fast chemical cleavage was observed in phosphate buffer at pH 7.4 [15,19,26,27], which indicated preferential basic hydrolysis of the ester bond. Thus, the free bases are expected to be rather sensitive toward traces of water during storage and handling since the pH environment should be fairly neutral. In contrast, the hydrochloride salts should generate a more acidic environment in the presence of water traces and remain more stable.

2.2. Chemical and enzymatic stability studies

The stabilities of the synthesized amino acid ester prodrugs of N5 (**11–19**) and the 5'-glycine prodrug of N5-2OH (**21**) toward hydrolysis were evaluated in three different media: 1) PBS to examine their chemical hydrolysis, 2) Bovine serum to evaluate their enzymatic hydrolysis, and 3) Bovine CSF. The protein composition of the latter medium is similar to that of the ISF of the brain [10,28]. Thus, it seems likely that the hydrolysis pattern of amino acid ester prodrugs under conditions similar to those they may encounter following i.c. injection can be established in CSF. Valacyclovir (**4**) was evaluated as a reference compound in all three media.

2.2.1. Chemical (non-enzymatic) hydrolysis in PBS at pH 7.4

The hydrolytic half-lives ($t_{1/2}$) of the prodrugs, measured by using the linear regression of pseudo-first-order plots of the remaining prodrug concentrations versus the hydrolysis times, are shown in Table 1. The obtained results clearly indicate that the hydrolysis rates of the amino acid ester prodrugs primarily depend on the amino acid promoieties. The glycine ester prodrugs of N5 (**14–16**) and the 5'-glycine ester prodrug of N5-2OH (**21**) are 20–25 times more sensitive to chemical hydrolysis than the corresponding glutamate- (**17–19**) and valine ester prodrugs (**11–13**) of N5. The sensitivity of **14–16** and **21** may be due to the presence of the small glycine promoiety, which is sterically not interfering with the nucleophilic hydrolytic attack at the ester bond.

Although **4**, **11**, and **12** are all monovaline esters, the half-life of **4** is ~2 times shorter than those of **11** and **12**. This difference may be due to the presence of the lipophilic carborane cage in **11** and **12**, which reduces their solubility, and hence, limits their accessibility to chemical hydrolysis. Song et al. [15] reported a half-life of 17.15 h for the chemical hydrolysis of **4**, which is somewhat longer than the value we found in our studies (13.6 h), but still comparable.

Compounds **17**–**19** appear to have intermediate stability toward chemical hydrolysis. In previous studies [19], the γ -glutamate ester prodrug of acyclovir exhibited significant chemical stability with a half-life of 28.2 h in PBS at pH 7.4, which is more than 2 times longer than the half-life we found for **18** in our studies.

The site of esterification also influences the rate of the hydrolysis of the amino acid ester prodrugs. Generally, 3'-monosubstituted amino acid ester prodrugs were more stable toward chemical hydrolysis than the corresponding 5'-monosubstituted amino acid ester prodrugs, which is consistent with reported data for floxuridine amino acid ester prodrugs [29], but in contrast to those found for amino acid ester prodrugs of gemcitabine [15]. The preference for the cleavage of the 5'-promoiety may be due to steric effects since the 3'-position is generally more crowded by the ribofuranose ring thereby interfering with the rate of the hydrolysis.

In general, the 3',5'-disubstituted amino acid ester prodrugs of N5 showed the shortest half-lives (Table 1). This result is consistent with previously reported data for the amino acid ester prodrugs of floxuridine [29] and gemcitabine [15]. This finding seems plausible as their half-lives not only depend on the hydrolysis to the parental compounds, but also on the conversion into the corresponding 3'- and 5'-monosubstituted amino acid ester prodrugs. On the other hand, the presence of two promoiety in these structures decreases, of course, the rate of production of parental compounds by a factor of ~2 compared with 5'-monosubstituted amino acid ester prodrugs (data not shown). In the case of **17**–**19**, the half-life of the 3',5'-diglutamate ester prodrug of N5 (**19**) is significantly shorter than those of the corresponding 3'- (**17**) and 5'-glutamate (**18**) esters. This may be due to the observed high solubility of **19** in PBS, which may increase access of the molecule to hydrolyzing conditions.

Compound **12**, as a representative of the very stable prodrugs, **18**, as a representative of the medium stable prodrugs, and **15**, as an example of the more sensitive prodrugs, were chosen for further studies in Bovine serum and Bovine CSF. Low synthetic yields of the 3'-monosubstituted amino acid ester prodrugs (~2 times lower than the corresponding 5'-monosubstituted amino acid ester prodrugs) and the special characteristics of the 3',5'-disubstituted amino acid ester prodrugs were major reasons for their exclusion from further stability assays. The same observations and the fact that **14**–**16** were generally most sensitive to chemical hydrolysis provided the rationale for limiting preparative efforts to the synthesis of the 3'-mono- (**20**), 5'-mono- (**21**), and 3',5'-diglycine (**22**) ester prodrugs of N5-2OH (section 2.1.) and evaluating exclusively the stability of **21** in all three test media.

2.2.2. Enzymatic stability studies

2.2.2.1. Stability studies in Bovine serum. The *in vitro* enzymatic hydrolysis pattern of the amino acid ester prodrugs was studied in Bovine serum at 37 °C. The hydrolytic half-lives of the prodrugs are shown in Table 1. The hydrolysis rates of **4**, **12**, **18**, and **21** in Bovine serum are 2.2-, 1.2-, 13.1- and 1.5 times, respectively, faster than the corresponding rates in PBS. These findings are consistent with previously reported results for other amino acid ester prodrugs [14,15,19]. They clearly indicate that the hydrolysis of the amino acid ester prodrugs is generally facilitated by enzymatic catalysis or protein-aided hydrolysis. However, the hydrolysis pattern of **15** in PBS did not change in serum. This may be due to the fact that

chemical hydrolysis is already so fast that the contribution of enzyme activity becomes negligible.

The rate of the hydrolysis of the amino acid ester prodrugs in serum was also influenced by the amino acid promoiety. In particular **18** appears to depend significantly stronger on enzymatic (protein-aided) cleavage than the other prodrugs. The enzymatic cleavage of **4** is 2.6 times more rapid than that of **12**. Song et al. [15] reported a half-life of 5.2 h for the hydrolysis of **4** in human plasma, which is comparable with the half-life of 6.2 h found in our studies with Bovine serum. The difference between the half-lives of **12** in PBS and Bovine serum (25.59 ± 0.61 vs. 22.21 ± 0.52) is relatively small indicating that it is in contrast to **4** not a good substrate for any degrading enzymes.

2.2.2.2. Stability studies in CSF. The hydrolysis patterns of **4**, **12**, **15**, **18**, and **21** were also studied in Bovine CSF at 37 °C for various time intervals and the data are presented in Table 1. It appears that the rate of the hydrolysis of the amino acid ester prodrugs in Bovine CSF is overall faster than in PBS and somewhat slower than in Bovine serum. The protein content in the Bovine CSF (Biochemed Services, Winchester, Virginia) was determined by the Bradford protein assay (see section 4.4.) and was found to be 150 times lower than the protein content in Bovine serum, which is somewhat higher than previously reported (260 times lower) [10]. Although a low protein (enzyme) concentration is present in the CSF, enzymatic degradation may be possible causing an increased rate of the hydrolysis in the CSF compared with PBS. This is especially the case for the hydrolysis rate of **18**, which is 6 times faster than in PBS. The dramatic increase in the rate of the hydrolysis of **18** in the CSF may be due to the presence of glutamate-specific enzymes in the CSF, as glutamate is the most common neurotransmitters in the brain [30].

2.2.3. Solubility studies

The solubilities of **1**, **2**, and **4** and the hydrochloride salts of **12**, **15**, **18**, and **21** were determined in PBS at pH 5, pH 6 and pH 7.4 at 37 °C (Table 2). The pHs of these PBS solutions were controlled before and after the addition of the amino acid ester prodrugs with pH-indicator strips (ColorpHast®, Merck, Darmstadt, Germany) and no changes were observed. Overall, the obtained data are in agreement with the estimated pKa values for the amino acid ester prodrugs (Table 2). Compound **12** is ~1–7 times more soluble than compounds **15** and **21**, as the former has a slightly higher estimated pKa value. On the other hand, **4** is ~1.5–3 times more soluble than **12**. The estimated water solubilities for **4** were 84 g/L at pH 5, 12 g/L at pH 6, and 1.4 g/L at pH 7.4 (Advanced Chemistry Development [ACD/Labs] software within Scifinder Scholar®), which are almost identical to those we measured in our study. On the other hand, Beauchamp et al. [21] determined the solubility of **4** in aqueous solution with 174 mg/mL. Although **12** has a higher estimated pKa value than **4** (7.85 vs 7.47, Table 2), the latter showed better solubility. The differences in the solubility between **4** and **12** may be due to the presence of the lipophilic carborane cage [31–34] in the latter compound.

Compound **21** showed slightly better solubilities than **15**, which was expected due to the presence of two additional hydroxyl groups in the former. The measured solubilities for **18** were moderate at all three pH levels and increased only slightly from 1.13 g/L at pH 5 to 1.77 g/L at pH 7.4. This is probably due to the presence of the additional carboxylic function with an estimated pKa of 2.20 (Table 2), and thus, zwitterion formation in the pH range of 5–7.4. Zwitterions can form strong intramolecular ion–ion interactions that interfere with the formation of ion–dipole interactions with water molecules, thereby reducing water-solubility [35].

All evaluated prodrugs showed significantly increased solubilities compared with their parental drugs. Depending on the pH

level in the test media, **12** is 327–6600 times more soluble than **1**, **18** is 282–443 times more soluble than **1**, and **15** and **21** are 48–2748 and 78–1400 times more soluble than **1** and **2**, respectively.

In preclinical BNCT studies with rats bearing intracerebral glioma [3], 200 μ L of a solution of 2.5 g of **2** in 1 L of a mixture of 35% DMSO and 65% of water was injected i.c. The solubility data shown in Table 2 demonstrate that similar concentrations can be achieved successfully with all tested prodrugs under aqueous conditions. Compound **12** showed the highest solubility, in particular at pH 5. Unfortunately, this amino acid ester prodrug does not seem to be a suitable candidate for further consideration because of its stability to chemical and enzymatic hydrolysis. Compounds **15** and **21** showed adequate solubilities at pH 5 and pH 6, whereas **18** had its highest solubility at pH 7.4. This may allow for the formulation of the latter amino acid ester prodrug at physiological pH for i.c. administration because it is fairly stable to chemical hydrolysis at pH 7.4 (see Table 1). In contrast, **15** and **21** require slightly acidic pH for appropriate solubilization. The possibility of administration at physiological pH may be an advantage of **18** compared with **15** and **21** because it may reduce toxic side effects.

3. Summary and conclusions

Novel improved strategies were developed for the synthesis of **1** and **10**. All proposed amino acid ester prodrugs of N5 (**11**–**19**) and N5-2OH (**20**–**22**) were successfully prepared. Notable are the inherently low overall yields for the synthesized prodrugs, in particular those for the 3'-monosubstituted amino acid ester prodrugs.

The rate of the hydrolysis of the amino acid ester prodrugs of **1** and **2** in the three incubation media depends primarily on the amino acid promoity, and to lesser extend, on the site of esterification at the deoxyribose portion. Generally, 3'-monosubstituted amino acid ester prodrugs were more stable to chemical hydrolysis than 5'-monosubstituted amino acid ester prodrugs. The 5'-valine ester prodrug **12** is the most stable both to enzymatic and non-enzymatic hydrolysis, the 5'-glycine acid ester prodrugs **15** and **21** are the most sensitive under both conditions, whereas the 5'-glutamate ester prodrug **18** shows intermediate stability to chemical hydrolysis and high sensitivity to cleavage in serum and CSF. The high sensitivity of **15** and **21** and the stability of the **12** to hydrolysis are in agreement with the results of previous stability studies with prodrugs of metronidazole [14] and gemcitabine [15]. In all three incubation media, the hydrolysis of valacyclovir (**4**) was faster than that of **12**. In contrast to **4**, however, **12** is notably less susceptible to enzymatic or protein-aided cleavage, indicating that it is not a good substrate for any degrading enzymes. Compounds **15** and **21** appeared to be least affected by enzymatic or protein-aided cleavage, as their half-lives did not vary significantly in all three media. Overall, the observed solubilities for all tested amino acid ester prodrugs at pH 5, 6, and 7.4 are significantly better than those of **1** and **2** and appeared to be suitable for i.c. injection. As discussed earlier, the fundamental prerequisite for amino acid ester prodrugs of **1** and **2** must be rapid cleavage to enable 5'-monophosphorylation. This requirement is fulfilled in the cases of **15** and **21**. Also, **18** seems to be a suitable candidate for preclinical BNCT studies because it showed rapid cleavage in CSF combined with moderate stability in PBS at pH 7.4.

4. Experimental section

4.1. Chemistry

NMR spectra were obtained on a Bruker Avance 400 at The Ohio State University College of Pharmacy (400 MHz for ^1H and 100 MHz for ^{13}C). Chemical shifts are reported in parts per million (ppm). The coupling constants are reported in Hertz (Hz). High Resolution-

Electrospray Ionization (HR-ESI) mass spectra were recorded on a Micromass LCT Electrospray mass spectrometer at The Ohio State University Campus Chemical Instrumentation Center (OSU-CCIC). For all carborane-containing compounds, the mass of the most intensive peak of the isotopic pattern was reported for an 80% boron-11–20% boron-10 distribution. Compound visualization on Silica Gel 60 F₂₅₄ precoated TLC plates (0.25 mm layer thickness) (Merck, Darmstadt, Germany) was attained by UV light and KMnO₄ spray. Carborane-containing compounds were selectively visualized by spraying a solution of 0.06% PdCl₂/1% aqueous HCl on TLC plates and subsequent heating to $\sim 120^\circ\text{C}$. Reagent grade solvents were used for column chromatography using Silica gel 60, particle size 63–200 μm (Dynamic Adsorbents, Inc, Georgia). Standard reagent grade chemicals were obtained from commercial vendors and used as such. *o*-Carborane was purchased from Katchem, Ltd, Prague, Czech Republic. Valacyclovir was purchased from Toronto Research Chemicals, Inc. Canada. Solvents were dried prior to use following standard procedures. All chemical reactions were carried out under argon atmosphere. Bovine serum and phosphate buffered saline (PBS) were obtained from Sigma–Aldrich. Bovine cerebrospinal fluid (CSF) was obtained from Biochemed Services, Winchester (Virginia). Filters (Corning, Germany) used in the stability studies had 0.2 μm pore size. The colorimetric measurement of protein concentrations in Bovine serum and Bovine CSF was carried out by using a Spectramax Plus Spectrophotometer from Molecular Devices (Sunnyvale, California). The obtained data were analyzed using SoftMax Pro 3.1.2 software.

Preparative HPLC was performed on a Gemini 5 μ C18 column (21.20 mm \times 250 mm, 5 μm particle size) from Phenomenex Inc. CA, USA using a Hitachi HPLC system (I-2130) with a Windows based data acquisition and a Hitachi Diode array detector (I-2455). Purification was accomplished using a water (0.1% TFA)/methanol gradient at 7 mL/min flow rate (100:0 to 50:50 over 15 min then 50:50 to 15:85 [H₂O:MeOH] over 70 min followed by 15:85 to 0:100 over 15 min).

Analytical HPLC for purity confirmation and stability analysis was carried out with a Gemini 5 μ C18 110A Column (250 \times 4.6 mm) from Phenomenex Inc. CA, USA using the HPLC system above. Two different solvent systems were used at 1 mL/min flow rate: A = water (0.1% TFA)/acetonitrile (0.1% TFA); B = water (0.1% TFA)/methanol (0.1% TFA). For each solvent system, different gradients were used for compound analysis (Table 3, A1–A4, B1–B3). For all Thd derivatives, a wavelength of 265 nm was used for detection, whereas valacyclovir/acyclovir were detected at 254 nm.

4.1.1. 5-[2-(*tert*-Butyldimethylsilyl)-*o*-carboran-1-yl]pentyl 4-methylbenzenesulfonate (**6**)

To a solution of **5** [24] (0.52 g, 2 mmol) in THF (50 mL) was added *n*-BuLi (0.9 mL, 2.36 mmol, 2.5 M solution in hexanes) at -78°C over a period of 10 min. The solution was gradually warmed to rt and then stirred for 1 h. Subsequently, the reaction mixture was cooled to 0°C and 1,5-pentandiol ditosylate (1.1 g, 2.6 mmol) was added dropwise. The mixture was refluxed at 80°C for 5 h. Distilled water (20 mL) was added and excess THF was removed under reduced pressure. The residue was extracted with ethyl acetate (30 mL \times 2). The combined organic layers were washed with diluted HCl solution (2%, 30 mL) and brine (30 mL), and dried over anhydrous MgSO₄. After filtration and evaporation, the residue was purified by silica gel column chromatography using hexanes/dichloromethane, 8:2, as the eluent to give compound **6** (0.35 g, 36%). *R*_f 0.70; ^1H NMR (CDCl₃): δ 0.28 (s, 6H, (CH₃)₂Si), 1.01 (s, 9H, (CH₃)₃C), 1.18–1.30 (m, 2H, C₂H₄CH₂), 1.36–1.46 (m, 2H, CH₂CH₂–C_{carborane}), 1.56–1.64 (m, 2H, OCH₂CH₂), 2.09 (t, *J* = 7.7 Hz, 2H, CH₂–C_{carborane}), 2.42 (s, 3H, CH₃), 3.96 (t, *J* = 6.1 Hz, 2H, OCH₂), 7.32 (d, *J* = 7.9 Hz, 2H, Ph), 7.74 (d, *J* = 7.9 Hz, 2H, Ph); ^{13}C NMR (CDCl₃): δ –1.53 ((CH₃)₂Si), 21.24 ((CH₃)₃C), 22.59 (CH₃), 25.96

(C₂H₄CH₂), 28.45 ((CH₃)₃C), 29.34 (CH₂CH₂–C_{carborane}), 30.38 (OCH₂CH₂), 38.55 (CH₂–C_{carborane}), 70.82 (CH₂O), 77.12, 82.10 (C_{carborane}), 128.76, 130.83, 133.84, 145.38 (Ph); MS (HR-ESI) calcd for C₂₀H₄₂B₁₀O₃SSiNa (M + Na)⁺: 521.3525, found: 521.3434.

4.1.2. 3-(5-{2-[*tert*-Butyldimethylsilyl]-*o*-carboran-1-yl}pentan-1-yl)thymidine (**7**)

To a solution of compound **6** (0.35 g, 0.71 mmol) in a mixture of DMF and acetone (30 mL, 1:1) were added Thd (0.86 g, 3.55 mmol) and potassium carbonate (0.59 g, 4.26 mmol) and stirred at 50 °C for 6 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using ethyl acetate/methanol, 20:1, as the eluent to give compound **7** (0.26 g, 65%). *R*_f 0.5; ¹H NMR (CD₃OD): δ 0.37 (s, 6H, Si(CH₃)₂), 1.09 (s, 9H, C(CH₃)₃), 1.27–1.37 (m, 2H, NC₂H₄CH₂), 1.54–1.65 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.91 (s, 3H, CH₃), 2.16–2.34 (m, 4H, CH₂–C_{carborane}, H-2'' and H-2'), 3.75 (dd, *J* = 11.8, and 3.3 Hz, 1H, H-5''), 3.82 (dd, *J* = 11.8, and 3.3 Hz, 1H, H-5'), 3.87–3.96 (m, 3H, CH₂N, and H-3'), 4.39–4.45 (m, 1H, H-4'), 6.31 (t, *J* = 6.8 Hz, 1H, H-1'), 7.85 (s, 1H, H-6), ¹³C NMR (CD₃OD): δ –2.94 (Si(CH₃)₂), 12.49 (CH₃), 20.38 ((CH₃)₃C), 26.47 (NC₂H₄CH₂), 27.25 ((CH₃)₃C), 30.14 (CH₂CH₂–C_{carborane}, NCH₂CH₂), 38.01 (CH₂–C_{carborane}), 40.50 (CH₂N), 41.02 (C-2'), 61.82 (C-5'), 71.15 (C-3'), 76.88, 82.24 (C_{carborane}), 86.10 (C-1'), 87.87 (C-4'), 109.70 (C-5), 135.48 (C-6), 151.24 (C-2), 164.30 (C-4); MS (HR-ESI) calcd for C₂₃H₄₈B₁₀N₂O₅SiNa (M + Na)⁺: 591.4233, found: 591.4304.

4.1.3. 3-(5-{*o*-Carboran-1-yl}pentan-1-yl)thymidine (**1**) [22,23]

To a solution of compound **7** (0.35 g, 0.62 mmol) in THF (30 mL) was added a 1 M solution of TBAF (1.0 mL, 1 mmol) in THF at –78 °C. The reaction mixture was stirred at rt for 0.5 h. Distilled water (10 mL) was added and excess THF was removed under reduced pressure. The residue was extracted with ethyl acetate (50 mL × 2), the combined organic layers were washed with brine (10 mL) and dried over anhydrous MgSO₄. After filtration and evaporation, the residue was subjected to silica gel column chromatography using ethyl acetate/methanol, 20:1, as the eluent to give compound **1** (0.17 g, 58%). *R*_f 0.6; ¹H NMR (CD₃OD) δ 1.28–1.37 (m, 2H, NC₂H₄CH₂), 1.49–1.66 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.17–2.33 (m, 4H, CH₂–C_{carborane}, H-2'', and H-2'), 3.74 (dd, *J* = 11.8, and 3.3 Hz, 1H, H-5''), 3.81 (dd, *J* = 11.8, and 3.3 Hz, 1H, H-5'), 3.88–3.95 (m, 3H, CH₂N, and H-3'), 4.39–4.44 (m, 1H, H-4'), 4.53 (s, 1H, carboranyl-CH), 6.31 (t, *J* = 6.4 Hz, 1H, H-1'), 7.85 (s, 1H, H-6); MS (HR-ESI) calcd for C₁₇H₃₄B₁₀N₂O₅Na (M + Na)⁺: 477.3369, found: 477.3546.

4.1.4. 4-(2-{5-Iodopentyl}-*o*-carboran-1-yl)methyl-2,2-dimethyl-1,3-dioxolane (**9**)

To a solution of compound **8** [25] (2.58 g, 10 mmol) in THF (50 mL) was added a solution of *n*-BuLi (4.8 mL, 12 mmol, 2.5 M solution in hexanes) at –78 °C. The reaction mixture was allowed to warm up to 0 °C and 1,5-diiodopentane (5.83 g, 18 mmol) was added dropwise in rapid fashion. The reaction mixture was refluxed at 80 °C for 6 h. Distilled water (30 mL) was added and excess THF was removed under reduced pressure. The residue was extracted with ethyl acetate (50 mL × 2), and the combined organic layers were washed with brine (10 mL) and dried over anhydrous MgSO₄. After filtration and evaporation, the residue was purified by silica gel column chromatography using hexanes/dichloromethane, 7:4, as the eluent to give compound **9** (1.85 g, 41%). *R*_f 0.3; ¹H NMR ((CD₃)₂CO): δ 1.31–1.45 (m, 8H, C(CH₃)₂, NC₂H₄CH₂), 1.50–1.62 (m, 2H, CH₂CH₂–C_{carborane}), 1.78–1.87 (m, 2H, ICH₂CH₂), 2.16–2.33 (m, 2H, CH₂–C_{carborane}), 2.39 (dd, *J* = 11.9, and 3.4 Hz, 1H, CHCH₂–C_{carborane}), 2.42 (dd, *J* = 11.9, and 3.4 Hz, 1H,

CHCH₂–C_{carborane}), 3.17 (t, *J* = 6.8 Hz, 2H, ICH₂), 3.55 (dd, *J* = 11.9 and 3.4 Hz, 1H, CH₂O), 4.13 (dd, *J* = 11.9 and 3.6 Hz, 1H, CHCH₂O), 4.21–4.30 (m, 1H, CH₂CHO); ¹³C NMR ((CD₃)₂CO): δ 6.92 (CH₂I), 25.80 (CH₃), 27.35 (CH₃), 29.07 (C₂H₄CH₂), 30.52 (CH₂CH₂–C_{carborane}), 33.20 (ICH₂CH₂), 35.32 (CH₂–C_{carborane}), 39.92 (CH₂–C_{carborane}), 69.51 (CH₂O), 74.87 (CHO), 77.44, 80.22 (C_{carborane}), 110.02 (C(CH₃)₂); MS (HR-ESI) calcd for C₁₃H₃₁B₁₀O₂Na (M + Na)⁺: 477.2270, found: 477.2257.

4.1.5. 3-(5-{2-[(2,2-Dimethyl-1,3-dioxolane-4-yl)methyl]-*o*-carboran-1-yl}pentan-1-yl)thymidine (**10**) [25]

To a solution of compound **9** (1.67 g, 3.68 mmol) in a mixture of DMF and acetone (50 mL, 1:1) were added Thd (4.45 g, 18.4 mmol) and potassium carbonate (3.05 g, 22.1 mmol) and stirred at 50 °C overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using ethyl acetate/methanol, 20:1, as the eluent to give compound **10** (1.0 g, 48%). *R*_f 0.29; ¹H NMR (CD₃OD): δ 1.29–1.42 (m, 8H, (CH₃)₂C, NC₂H₄CH₂), 1.57–1.69 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.17–2.40 (m, 4H, CH₂–C_{carborane}, H-2'', and H-2'), 2.54 (dd, *J* = 11.9, and 3.4 Hz, 1H, CHCH₂–C_{carborane}), 2.61 (dd, *J* = 11.9, and 3.4 Hz, 1H, CHCH₂–C_{carborane}), 3.56 (t, *J* = 6.8 Hz, 1H, CH₂O), 3.74 (dd, *J* = 11.9, and 3.4 Hz, 1H, H-5''), 3.82 (dd, *J* = 11.9, and 3.4 Hz, 1H, H-5'), 3.88–3.96 (m, 3H, CH₂N, and H-3'), 4.06–4.14 (m, 1H, CH₂O), 4.20–4.32 (m, 1H, CH₂CHO), 4.38–4.44 (m, 1H, H-4'), 6.32 (t, *J* = 6.8 Hz, 1H, H-1'), 7.86 (s, 1H, H-6).

4.1.6.a. General procedure for the synthesis of the amino acid ester prodrugs of N5 (11–19**) and the glycine ester prodrugs of N5-2OH (**20–22**).** Compound **1** (0.22 mmol) or **10** (0.18 mmol), N-Boc-amino acid (Boc-L-valine, Boc-glycine, or Boc-L-glutamic acid *α*-*tert*-butyl ester) (0.44/0.36 mmol), DCC (0.44/0.36 mmol) and DMAP (0.044/0.036 mmol) were dissolved in 10 mL of anhydrous DMF. The reaction mixture was stirred at rt for 24 h. The progress of the reaction was monitored by TLC (ethyl acetate:hexanes, 8:5). The reaction yielded three products as determined by TLC. After 24 h, the reaction mixture was filtered and DMF was removed in vacuum. The residue was dissolved in ethyl acetate (30 mL) and washed with water (20 mL), 0.1 N HCl (20 mL), saturated NaHCO₃ (20 mL), and brine (20 mL). The organic layer was dried over anhydrous MgSO₄. The three intermediates observed by TLC were separated and purified partially by column chromatography (ethyl acetate: hexane, 8:5; see supplementary material for ¹H NMR data and *R*_f values for Boc-protected intermediates). Individual Boc-substituted amino acid ester prodrugs were added to 10 mL of a mixture of trifluoroacetic acid (TFA) and dichloromethane (1:1) and stirred at rt for 2 h (Boc-L-glutamic acid 5-*tert*-butyl esters were stirred for 4 h). The solvent was removed and the amino acid ester prodrugs were purified by preparative HPLC to give products **11–22** as wax-like compounds.

4.1.6.b. General procedure for the synthesis of the hydrochloride salts of the amino acid ester prodrugs **11–13 and **15–22**.** To a solution of the amino acid ester prodrug (**11–13** and **15–22**) [0.2 mmol] in diethyl ether/THF (1/1, 2 mL) was added 1 mL of a 1 M solution of HCl gas in diethyl ether at 0 °C and stirred overnight at rt. The solvent was removed under reduced pressure and the oily residue was solidified by adding 5 mL of a 0.1 M solution of HCl gas in diethyl ether. The obtained solid was washed 3–4 times with a 0.1 M solution of HCl gas in diethyl ether to give product (**11–13•HCl** and **15–22•HCl**) in 50%–70% yield.

4.1.6.1. 3'-L-valyl-3-(5-{*o*-carboran-1-yl}pentan-1-yl)thymidine (11**).** Yield: 6 mg, 5%; ¹H NMR (CD₃OD): δ 1.11 (d, *J* = 4.6 Hz, 6H, CH(CH₃)₂),

1.28–1.38 (m, 2H, NC₂H₄CH₂), 1.48–1.68 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.21–2.50 (m, 5H, CH₂–C_{carborane}, H-2'', H-2', and CH(CH₃)₂), 3.82–3.85 (m, 2H, H-5'' and H-5'), 3.90 (t, *J* = 6.8 Hz, 2H, CH₂N), 4.09 (d, *J* = 4.6 Hz, 1H, CHNH₂), 4.14–4.18 (m, 1H, H-4'), 4.52 (s, 1H, carboranyl-CH), 5.48–5.52 (m, 1H, H-3'), 6.34 (t, *J* = 6.8 Hz, 1H, H-1'), 7.86 (s, 1H, H-6); ¹³C NMR (CD₃OD): δ 12.69 (CH₃), 17.87 (CH(CH₃)₂), 26.59 (NC₂H₄CH₂), 27.39 (CH₂CH₂–C_{carborane}), 29.42 (NCH₂CH₂), 30.54 (CH(CH₃)₂), 37.89 (CH₂–C_{carborane}), 38.04 (CH₂N), 41.42 (C-2'), 58.81 (CHNH₂), 62.29 (C_{carborane}), 63.14 (C-5'), 76.75 (C_{carborane}), 78.24 (C-3'), 85.78 (C-1'), 86.52 (C-4'), 110.69 (C-5), 135.56 (C-6), 151.86 (C-2), 164.76 (C-4), 169.20 (COO); MS (HR-ESI) calcd for C₂₂H₄₄B₁₀N₃O₆ (M + H)⁺: 554.4233, found: 554.4145; **11**•HCl: Anal. (C₂₂H₄₄B₁₀ClN₃O₆) C, H, N.

4.1.6.2. 5'-L-valyl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (12). Yield: 12 mg, 10%; ¹H NMR (CD₃OD): δ 1.04–1.09 (m, 6H, CH(CH₃)₂), 1.25–1.34 (m, 2H, NC₂H₄CH₂), 1.46–1.63 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.91 (s, 3H, CH₃), 2.23–2.36 (m, 5H, CH₂–C_{carborane}, H-2'', H-2', and CH(CH₃)₂), 3.89 (t, *J* = 7.2 Hz, 2H, CH₂N), 3.97 (d, *J* = 4.4 Hz, 1H, CHNH₂), 4.06–4.13 (m, 1H, H-3'), 4.32–4.37 (m, 1H, H-4'), 4.41 (dd, *J* = 11.8, and 3.3 Hz, 1H, H-5''), 4.52 (s, 1H, carboranyl-CH), 4.56–4.64 (m, 1H, H-5'), 6.27 (t, *J* = 6.8 Hz, 1H, H-1'), 7.46 (s, 1H, H-6); ¹³C NMR (CD₃OD): δ 12.68 (CH₃), 17.65, 17.76 (CH(CH₃)₂), 26.62 (NC₂H₄CH₂), 27.41 (CH₂CH₂–C_{carborane}), 29.44 (NCH₂CH₂), 30.55 (CH(CH₃)₂), 38.05 (CH₂–C_{carborane}), 39.59 (CH₂N), 41.42 (C-2'), 58.86 (CHNH₂), 63.16 (C_{carborane}), 66.56 (C-5'), 71.61 (C-3'), 76.76 (C_{carborane}), 84.64 (C-1'), 87.37 (C-4'), 110.58 (C-5), 135.92 (C-6), 151.66 (C-2), 164.75 (C-4), 169.55 (COO); MS (HR-ESI) calcd for C₂₂H₄₄B₁₀N₃O₆ (M + H)⁺: 554.4233, found: 554.4227, calcd for C₂₂H₄₃B₁₀N₃O₆Na (M + Na)⁺: 576.4053 (M + Na)⁺, found 576.4076; **12**•HCl: Anal. (C₂₂H₄₄B₁₀ClN₃O₆) C, H, N.

4.1.6.3. 3',5'-di-L-valyl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (13). Yield: 18 mg, 13%; ¹H NMR (CD₃OD): δ 1.05 (d, *J* = 4.4 Hz, 6H, CH(CH₃)₂), 1.10 (d, *J* = 4.4 Hz, 6H, CH(CH₃)₂), 1.26–1.35 (m, 2H, NC₂H₄CH₂), 1.47–1.63 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.23–2.38 (m, 4H, CH₂–C_{carborane}, H-2'' and H-2'), 2.50–2.57 (m, 1H, CH(CH₃)₂), 2.61–2.70 (m, 1H, CH(CH₃)₂), 3.89 (t, *J* = 6.8 Hz, 2H, CH₂N), 3.98 (d, *J* = 4.4 Hz, 1H, CHNH₂), 4.02 (d, *J* = 4.4 Hz, 1H, CHNH₂), 4.33–4.39 (m, 1H, H-4'), 4.45–4.55 (m, 2H, carboranyl-CH and H-5''), 4.68–4.74 (m, 1H, H-5'), 5.46–5.50 (m, 1H, H-3'), 6.23 (t, *J* = 6.8 Hz, 1H, H-1'), 7.47 (s, 1H, H-6); ¹³C NMR (CD₃OD) δ 12.16 (CH₃), 17.17, 17.24, 17.36, 17.39 (2CH(CH₃)₂), 26.09 (NC₂H₄CH₂), 26.89 (CH₂CH₂–C_{carborane}), 28.91 (NCH₂CH₂), 30.04 (2CH(CH₃)₂), 35.96 (CH₂–C_{carborane}), 37.55 (CH₂N), 40.91 (C-2'), 58.32 (2CHNH₂), 62.69 (C_{carborane}), 65.51 (C-5'), 72.28 (C_{carborane}), 76.31 (C-3'), 81.89 (C-1'), 87.71 (C-4'), 110.32 (C-5), 135.72 (C-6), 151.14 (C-2), 164.13 (C-4), 168.83, 169.07 (2COO); MS (HR-ESI) calcd for C₂₇H₅₃B₁₀N₄O₇ (M + H)⁺: 653.4917, found: 653.4932; **13**•HCl: Anal. (C₂₇H₅₄B₁₀Cl₂N₄O₇) C, H, N.

4.1.6.4. 3'-glycyl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (14). Yield: 1 mg, 1%; ¹H NMR (CD₃OD): δ 1.22–1.34 (m, 2H, NC₂H₄CH₂), 1.44–1.63 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.89 (s, 3H, CH₃), 2.20–2.48 (m, 4H, CH₂–C_{carborane}, H-2'' and H-2'), 3.87–3.94 (m, 6H, CH₂N, CH₂NH₂, H-5'' and H-5'), 4.12–4.17 (m, 1H, H-4'), 4.49 (s, 1H, carboranyl-CH, and), 5.45–5.55 (m, 1H, H-3'), 6.32 (t, *J* = 6.7 Hz, 1H, H-1'), 7.83 (s, 1H, H-6); ¹³C NMR (CD₃OD): δ 13.07 (CH₃), 26.99 (NC₂H₄CH₂), 27.78 (CH₂CH₂–C_{carborane}), 29.82 (NCH₂CH₂), 38.27 (CH₂–C_{carborane}), 38.43 (NCH₂), 41.02 (CH₂NH₂), 41.82 (C-2'), 62.71 (C_{carborane}), 63.53 (C-5'), 77.13 (C_{carborane}), 78.49 (C-3'), 86.22 (C-1'), 86.82 (C-4'), 111.08 (C-5), 135.92 (C-6), 152.25 (C-2), 165.13 (C-4), 168.17 (COO); MS (HR-ESI) calcd for C₁₉H₃₈B₁₀N₃O₆ (M + H)⁺: 512.3764, found: 512.5839.

4.1.6.5. 5'-glycyl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (15). Yield: 8 mg, 7%; ¹H NMR (CD₃OD): δ 1.25–1.35 (m, 2H, NC₂H₄CH₂), 1.44–1.64 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.23–2.35 (m, 4H, CH₂–C_{carborane}, H-2'' and H-2'), 3.84–3.95 (m, 4H, CH₂N, and CH₂NH₂), 4.04–4.10 (m, 1H, H-3'), 4.36–4.40 (m, 1H, H-4'), 4.44 (dd, *J* = 11.7, and 3.6 Hz, 1H, H-5''), 4.48–4.55 (m, 2H, carboranyl-CH, and H-5'), 6.26 (t, *J* = 6.7 Hz, 1H, H-1'), 7.46 (s, 1H, H-6); ¹³C NMR (CD₃OD): 12.20 (CH₃), 26.13 (NC₂H₄CH₂), 26.92 (CH₂CH₂–C_{carborane}), 28.94 (NCH₂CH₂), 37.56 (CH₂–C_{carborane}), 39.17 (NCH₂), 39.96 (CH₂NH₂), 40.94 (C-2'), 62.65 (C_{carborane}), 65.81 (C-5'), 71.05 (C-3'), 76.25 (C_{carborane}), 84.12 (C-1'), 86.63 (C-4'), 110.11 (C-5), 135.34 (C-6), 151.19 (C-2), 164.27 (C-4), 167.47 (COO); MS (HR-ESI) calcd for C₁₉H₃₈B₁₀N₃O₆ (M + H)⁺: 512.3764, found: 512.3798; **15**•HCl: Anal. (C₁₉H₃₈B₁₀ClN₃O₆) C, H, N.

4.1.6.6. 3',5'-di-glycyl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (16). Yield: 19 mg, 15%; ¹H NMR (CD₃OD): δ 1.24–1.36 (m, 2H, NC₂H₄CH₂), 1.48–1.64 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.26 (t, *J* = 6.8 Hz, 2H, CH₂–C_{carborane}), 2.50–2.62 (m, 2H, H-2'' and H-2'), 3.89–3.95 (m, 6H, CH₂N, and 2CH₂NH₂), 4.32–4.38 (m, 1H, H-4'), 4.48–4.55 (m, 2H, carboranyl-CH and H-5''), 4.60 (dd, *J* = 11.7, and 3.6 Hz, 1H, H-5'), 5.46–5.49 (m, 1H, H-3'), 6.25 (t, *J* = 6.7 Hz, 1H, H-1'), 7.48 (s, 1H, H-6); ¹³C NMR (CD₃OD): δ 13.33 (CH₃), 27.52 (NC₂H₄CH₂), 28.04 (CH₂CH₂–C_{carborane}), 30.08 (NCH₂CH₂), 37.17 (CH₂–C_{carborane}), 38.68 (NCH₂), 41.11, 41.26 (2CH₂NH₂), 42.09 (C-2'), 63.80 (C_{carborane}), 66.45 (C-5'), 77.39 (C_{carborane}), 77.49 (C-3'), 82.93 (C-1'), 88.20 (C-4'), 111.45 (C-5), 136.52 (C-6), 152.28 (C-2), 165.33 (C-4), 168.52, 168.58 (2COO); MS (HR-ESI) calcd for C₂₁H₄₁B₁₀N₄O₇ (M + H)⁺: 569.3978, found: 569.3975; **16**•HCl: Anal. (C₂₁H₄₂B₁₀Cl₂N₄O₇) C, H, N.

4.1.6.7. 3'-L-glutam-5-yl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (17). Yield: 3 mg, 2%; ¹H NMR (CD₃OD): δ 1.28–1.35 (m, 2H, NC₂H₄CH₂), 1.47–1.64 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.15–2.40 (m, 6H, CH₂–C_{carborane}, CH₂CHNH₂, H-2'' and H-2'), 2.64–2.69 (m, 2H, CH₂COO), 3.81–3.83 (m, 2H, H-5'' and H-5'), 3.90 (t, *J* = 6.8 Hz, 2H, CH₂N), 4.05 (t, *J* = 6.8 Hz, 1H, CHNH₂), 4.10–4.13 (m, 1H, H-4'), 4.52 (s, 1H, carboranyl-CH), 5.34–5.39 (m, 1H, H-3'), 6.31 (t, *J* = 6.8 Hz, 1H, H-1'), 7.86 (s, 1H, H-6); ¹³C NMR (CD₃OD): δ 12.19 (CH₃), 25.45 (CH₂CHNH₂), 26.12 (NC₂H₄CH₂), 26.91 (CH₂CH₂–C_{carborane}), 28.94 (NCH₂CH₂), 29.50 (CH₂COO), 37.51 (CH₂–C_{carborane}), 37.55 (NCH₂), 40.94 (C-2'), 52.00 (CHNH₂), 61.90 (C-5'), 62.66 (C_{carborane}), 75.97 (C-3'), 77.50 (C_{carborane}), 85.65 (C-1'), 85.98 (C-4'), 110.17 (C-5), 135.12 (C-6), 151.38 (C-2), 164.28 (C-4), 170.37 (COOCH₂), 172.15 (COOH). MS (HR-ESI) calcd for C₂₂H₄₁B₁₀N₃O₈Na (M + Na)⁺: 606.3795, found: 606.3813 (M + Na)⁺; **17**•HCl: Anal. (C₂₂H₄₂B₁₀ClN₃O₈) calcd: C, 42.61; H, 6.83; N, 6.78, found: C, 41.95; H, 6.54; N, 6.62.

4.1.6.8. 5'-L-glutam-5-yl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (18). Yield: 17 mg, 13%; ¹H NMR (CD₃OD): δ 1.28–1.35 (m, 2H, NC₂H₄CH₂), 1.46–1.64 (m, 4H, NCH₂CH₂, and CH₂CH₂–C_{carborane}), 1.92 (s, 3H, CH₃), 2.12–2.35 (m, 6H, CH₂–C_{carborane}, CH₂CHNH₂, H-2'' and H-2'), 2.66 (t, *J* = 6.9 Hz, 2H, CH₂COO), 3.89 (t, *J* = 6.9 Hz, 2H, CH₂N), 4.01–4.11 (m, 2H, CHNH₂, and H-3'), 4.30 (dd, *J* = 11.9 and 3.4 Hz, 1H, H-5''), 4.33–4.38 (m, 1H, H-4'), 4.41 (dd, *J* = 11.9 and 3.4 Hz, 1H, H-5'), 4.51 (s, 1H, carboranyl-CH), 6.28 (t, *J* = 6.8 Hz, 1H, H-1'), 7.49 (s, 1H, H-6); ¹³C NMR (CD₃OD): δ 12.29 (CH₃), 25.56 (CH₂CHNH₂), 26.13 (NC₂H₄CH₂), 26.91 (CH₂CH₂–C_{carborane}), 28.94 (NCH₂CH₂), 29.48 (CH₂COO), 37.55 (CH₂–C_{carborane}), 39.57 (NCH₂), 40.93 (C-2'), 51.99 (CHNH₂), 62.64 (C-5'), 64.56 (C_{carborane}), 71.22 (C-3'), 76.26 (C_{carborane}), 84.65 (C-1'), 86.47 (C-4'), 110.00 (C-5), 135.00 (C-6), 151.18 (C-2), 164.28 (C-4), 170.29 (COOCH₂), 172.32 (COOH); MS (HR-ESI) calcd for C₂₂H₄₁B₁₀N₃O₈Na (M + Na)⁺: 606.3795, found: 606.3793. **18**•HCl: Anal. (C₂₂H₄₂B₁₀ClN₃O₈) calcd: C, 42.61; H, 6.83; N, 6.78, found: C, 42.12; H, 6.74; N, 6.74.

4.1.6.9. 3',5'-di-L-glutam-5-yl-3-(5-{o-carboran-1-yl}pentan-1-yl)thymidine (19). Yield: 48 mg; ^1H NMR (CD_3OD): δ 1.28–1.35 (m, 2H, $\text{NC}_2\text{H}_4\text{CH}_2$), 1.45–1.64 (m, 4H, NCH_2CH_2 , and $\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 1.91 (s, 3H, CH_3), 2.10–2.28 (m, 4H, $\text{CH}_2\text{-C}_{\text{carborane}}$, H-2'', and H-2'), 2.35–2.50 (m, 4H, $2\text{CH}_2\text{CHNH}_2$), 2.62–2.69 (m, 4H, $2\text{CH}_2\text{COO}$), 3.89 (t, $J = 6.8$ Hz, 2H, CH_2N), 3.93–4.01 (m, 2H, 2CHNH_2), 4.26–4.31 (m, 1H, H-4'), 4.34 (dd, $J = 11.9$, and 3.4 Hz, 1H, H-5''), 4.47 (dd, $J = 11.9$, and 3.4 Hz, 1H, H-5'), 4.51 (s, 1H, carboranyl-CH), 5.29–5.33 (m, 1H, H-3'), 6.24 (t, $J = 6.8$ Hz, 1H, H-1'), 7.49 (s, 1H, H-6), ^{13}C NMR (CD_3OD): δ 12.32 (CH_3), 25.40, 25.54 ($2\text{CH}_2\text{CHNH}_2$), 26.12 ($\text{NC}_2\text{H}_4\text{CH}_2$), 26.90 ($\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 28.94 (NCH_2CH_2), 29.34, 29.52 ($2\text{CH}_2\text{COO}$), 36.66 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 37.55 (NCH_2), 40.97 (C-2'), 52.00 (2CHNH_2), 62.66 (C-5'), 64.36 ($\text{C}_{\text{carborane}}$), 76.20 (C-3'), 77.25 ($\text{C}_{\text{carborane}}$), 82.65 (C-1'), 86.59 (C-4'), 110.29 (C-5), 134.77 (C-6), 151.20 (C-2), 164.21 (C-4), 170.34, 170.38 (2COOCH_2), 172.17, 172.31 (2COOH); MS (HR-ESI) calcd for $\text{C}_{27}\text{H}_{48}\text{B}_{10}\text{N}_4\text{O}_{11}\text{Na}$ ($\text{M} + \text{Na}$) $^+$, 735.4220, found: 735.4203; **19**•HCl: Anal. ($\text{C}_{27}\text{H}_{50}\text{B}_{10}\text{Cl}_2\text{N}_4\text{O}_{11}$) C, H, N.

4.1.6.10. 3'-glycyl-3-[5-(2-{2,3-dihydroxyprop-1-yl}-o-carboran-1-yl)pentan-1-yl]thymidine (20). Yield: 4 mg, 4%; ^1H NMR (CD_3OD): δ 1.28–1.38 (m, 2H, $\text{NC}_2\text{H}_4\text{CH}_2$), 1.52–1.66 (m, 4H, NCH_2CH_2 , and $\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 1.89 (s, 3H, CH_3), 2.17–2.58 (m, 6H, $\text{CH}_2\text{-C}_{\text{carborane}}$, $\text{CHCH}_2\text{-C}_{\text{carborane}}$, H-2'' and H-2'), 3.33–3.49 (m, 2H, CH_2OH), 3.71–3.96 (m, 7H, CH_2N , CH_2NH_2 , H-5'', H-5' and CH_2CHO), 4.12–4.17 (m, 1H, H-4'), 5.44–5.49 (m, 1H, H-3'), 6.31 (t, $J = 6.7$ Hz, 1H, H-1'), 7.83 (s, 1H, H-6), ^{13}C NMR (CD_3OD): δ 13.37 (CH_3), 27.38 ($\text{NC}_2\text{H}_4\text{CH}_2$), 28.00 ($\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 30.49 (NCH_2CH_2), 35.93 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 38.55 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 40.03 (NCH_2), 41.32 (CH_2NH_2), 42.09 (C-2'), 62.98 (C-5'), 67.06 (CH_2OH), 72.35 (CHOH), 78.75 (C-3'), 80.57 ($\text{C}_{\text{carborane}}$), 82.00 ($\text{C}_{\text{carborane}}$), 86.47 (C-1'), 87.08 (C-4'), 111.34 (C-5), 136.16 (C-6), 152.51 (C-2), 165.40 (C-4), 16.46 (COO); MS (HR-ESI) calcd for $\text{C}_{22}\text{H}_{44}\text{B}_{10}\text{N}_3\text{O}_8$ ($\text{M} + \text{H}$) $^+$: 586.4132, found: 586.4059; **20**•HCl: Anal. ($\text{C}_{22}\text{H}_{44}\text{B}_{10}\text{ClN}_3\text{O}_8$) C, H, N.

4.1.6.11. 5'-glycyl-3-[5-(2-{2,3-dihydroxyprop-1-yl}-o-carboran-1-yl)pentan-1-yl]thymidine (21). Yield: 23 mg, 22%; ^1H NMR (CD_3OD): δ 1.24–1.37 (m, 2H, $\text{NC}_2\text{H}_4\text{CH}_2$), 1.51–1.63 (m, 4H, NCH_2CH_2 , and $\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 1.90 (s, 3H, CH_3), 2.18–2.38 (m, 4H, $\text{CH}_2\text{-C}_{\text{carborane}}$, H-2'' and H-2'), 2.52 (d, $J = 4.4$ Hz, 2H, $\text{CHCH}_2\text{-C}_{\text{carborane}}$), 3.27–3.36 (m, 1H, CH_2OH), 3.45 (dd, $J = 11.7$, and 3.6 Hz, 1H, CH_2OH), 3.72–3.80 (m, 1H, H-3'), 3.82–3.94 (m, 4H, CH_2N , and CH_2NH_2), 4.02–4.08 (m, 1H, CH_2CHO), 4.31–4.37 (m, 1H, H-4'), 4.41 (dd, $J = 11.7$, and 3.6 Hz, 1H, H-5''), 4.49 (dd, $J = 11.7$, and 3.6 Hz, 1H, H-5'), 6.24 (t, $J = 6.7$ Hz, 1H, H-1'), 7.44 (s, 1H, H-6); ^{13}C NMR (CD_3OD): δ 12.23 (CH_3), 26.29 ($\text{NC}_2\text{H}_4\text{CH}_2$), 26.91 ($\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 29.38 (NCH_2CH_2), 34.82 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 38.91 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 39.19 (NCH_2), 39.99 (CH_2NH_2), 40.99 (C-2'), 65.84 (C-5'), 65.93 (CH_2OH), 71.07 (CHOH), 71.22 (C-3'), 79.45 ($\text{C}_{\text{carborane}}$), 80.89 ($\text{C}_{\text{carborane}}$), 84.14 (C-1'), 86.67 (C-4'), 110.12 (C-5), 135.35 (C-6), 151.12 (C-2), 164.28 (C-4), 167.46 (COO); MS (HR-ESI) calcd $\text{C}_{22}\text{H}_{44}\text{B}_{10}\text{N}_3\text{O}_8$ ($\text{M} + \text{H}$) $^+$: 586.4132, found: 586.4107; **21**•HCl: Anal. ($\text{C}_{22}\text{H}_{44}\text{B}_{10}\text{ClN}_3\text{O}_8$) C, H, N.

4.1.6.12. 3',5'-di-glycyl-3-[5-(2-{2,3-dihydroxyprop-1-yl}-o-carboran-1-yl)pentan-1-yl]thymidine (22). Yield: 24 mg, 21%; ^1H NMR (CD_3OD): δ 1.25–1.38 (m, 2H, $\text{NC}_2\text{H}_4\text{CH}_2$), 1.53–1.64 (m, 4H, NCH_2CH_2 , and $\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 1.91 (s, 3H, CH_3), 2.20–2.39 (m, 4H, $\text{CH}_2\text{-C}_{\text{carborane}}$, H-2'' and H-2'), 2.46–2.61 (m, 2H, $\text{CHCH}_2\text{-C}_{\text{carborane}}$), 3.45 (dd, $J = 11.7$, and 3.6 Hz, 1H, CH_2OH), 3.71–3.80 (m, 1H, CH_2OH), 3.82–3.97 (m, 7H, CH_2N , $2\text{CH}_2\text{NH}_2$ and CH_2CHO), 4.32–4.37 (m, 1H, H-4'), 4.49 (dd, $J = 11.7$, and 3.6 Hz, 1H, H-5''), 4.59 (dd, $J = 11.7$, and 3.6 Hz, 1H, H-5'), 5.42–5.47 (m, 1H, H-3'), 6.23 (t, $J = 6.7$ Hz, 1H, H-1'), 7.46 (s, 1H, H-6); ^{13}C NMR (CD_3OD): δ 12.21 (CH_3), 26.25 ($\text{NC}_2\text{H}_4\text{CH}_2$), 26.86 ($\text{CH}_2\text{CH}_2\text{-C}_{\text{carborane}}$), 29.35 (NCH_2CH_2), 34.79 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 36.09 ($\text{CH}_2\text{-C}_{\text{carborane}}$), 38.89 (NCH_2), 39.97, 40.15 ($2\text{CH}_2\text{NH}_2$), 40.79 (C-2'), 65.41 (C-5'), 65.93 (CH_2OH), 71.21 (CHOH), 76.39 (C-3'), 79.44

($\text{C}_{\text{carborane}}$), 80.86 ($\text{C}_{\text{carborane}}$), 81.83 (C-1'), 87.16 (C-4'), 110.33 (C-5), 135.39 (C-6), 151.19 (C-2), 164.18 (C-4), 167.41, 167.47 (2COO); MS (HR-ESI) calcd for $\text{C}_{24}\text{H}_{47}\text{B}_{10}\text{N}_4\text{O}_9$ ($\text{M} + \text{H}$) $^+$: 643.4346, found: 643.4391; **22**•HCl: Anal. ($\text{C}_{24}\text{H}_{47}\text{B}_{10}\text{ClN}_4\text{O}_9$) calcd: C, 40.28; H, 6.76; N, 7.83, found: C, 40.36; H, 6.27; N, 7.53.

4.2. Stability studies

4.2.1. Stability studies in PBS at pH 7.4

Solutions of amino acid ester prodrugs **4**, **11**–**19**, and **21** in PBS (2 mM, 2.7 mL, pH 7.4) were incubated at 37 °C for 6–48 h depending on the degradation time of the prodrug. Aliquots of 200 μL from the incubated solutions were withdrawn at various time intervals and mixed with ice-cold TFA in acetonitrile solution (10%, 400 μL). The mixtures were passed through 0.2 μm filters and analyzed by HPLC (Table 3) to determine the areas under the curves (AUCs) that corresponded to the prodrugs and their degradation products.

4.2.2. Stability studies in Bovine serum

Solutions of amino acid ester prodrugs **4**, **12**, **15**, **18**, and **21** in Bovine serum (2 mM, 2.7 mL) were incubated at 37 °C for 6–48 h depending on the degradation profiles of the prodrugs. Aliquots of 200 μL from the incubation media were taken at various time points and added to ice-cold TFA in acetonitrile solutions (10%, 400 μL). The samples were centrifuged for 10 min at 3000 rcf, the supernatants were passed through 0.2 μm filters, and the filtrates were analyzed by HPLC (Table 3) to obtain AUCs.

4.2.3. Stability studies in Bovine CSF

Solutions of amino acid ester prodrugs **4**, **12**, **15**, **18**, and **21** in CSF (2 mM, 2.7 mL) were incubated at 37 °C for 6–48 h depending on the prodrug degradation profiles. Aliquots of 200 μL from each experiment were taken at various time intervals and mixed with ice-cold TFA in acetonitrile solution (10%, 400 μL). The samples were passed through 0.2 μm filters and analyzed by HPLC (Table 3) to give the corresponding AUCs.

4.2.4. Calculation of the degradation half-lives ($t_{1/2}$) of the amino acid ester prodrugs

The hydrolytic half-lives ($t_{1/2}$) of the amino acid ester prodrugs **4**, **11**–**19**, and **21** were calculated by utilizing the integrated AUCs from analytical HPLC data. The AUCs were converted into the remaining concentrations of the amino acid ester prodrugs using generated standard curves for the amino acid ester prodrugs. Standard curves for the amino acid ester prodrugs were generated by plotting different concentrations of the amino acid ester prodrug vs. the corresponding AUCs values. The apparent first-order degradation rate constants of the amino acid ester prodrugs **4**, **11**–**19**, and **21** were determined by plotting the logarithm of the remaining concentrations of the amino acid ester prodrug vs. time. The concentration–time curves were analyzed by a computerized a curve-stripping program (R Strip; Micromath Scientific Software, Salt Lake City, UT, USA). The slopes of these plots were related to the rate constant k given by the following relation:[15]

$$K = 2.303 \times \text{slope}(\log \text{Cvs.time})$$

The hydrolytic half-lives were then determined by the following equation:[15]

$$t_{1/2} = 0.693/k$$

4.3. Solubility studies

Quantities of 1 mg of the hydrochloric acid salts of the amino acid ester prodrugs **4**, **12**, **15**, **18**, and **21** or their corresponding parental drugs **1** and **2** were added to micro centrifuge tubes containing

either PBS (100 μ L, pH 5), PBS (100 μ L, pH 6) or PBS (100 μ L, pH 7.4). The micro centrifuge tubes were placed in a shaker for 4 h followed by centrifugation at 3000 rcf for 10 min. The solutions were passed through 0.2 μ m filters and analyzed by HPLC (Table 3) to obtain the AUC corresponding to amount of the drug soluble in the each buffer. Standard curves for the each amino acid ester prodrug and its parental compound were generated and utilized to calculate the amino acid ester prodrug concentration corresponding to each AUC.

4.4. Determination of the protein content of PBS, Bovine serum and CSF using the Bradford protein assay

Seven dilutions of the standard protein (Bovine serum albumin, BSA) were required to set up a standard curve. Ten μ L of each BSA concentration and 10 μ L of each sample (PBS, serum, CSF) were added into separate plate wells of a 96 well plate. The quantity of 500 μ L of 5-fold diluted Bradford reagent (BioRAD, Philadelphia) was added to each well. The plate was incubated in the dark at room temperature for 5 min. Following incubation, the absorbances of the different BSA concentrations and the samples were measured at 595 nm. A standard curve was generated by plotting the seven BSA concentrations vs. the corresponding absorbances. The standard curve was utilized to calculate the protein concentrations corresponding to the measured absorbance of each test sample.

Acknowledgments

This work was supported by funds from The Ohio State University College of Pharmacy, NIH Grant R01CA127935, and a scholarship from the Scholar Exchange Program of the Egyptian Education Ministry. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.ejmech.2012.07.033>. Data include original MS-, 1 H NMR-, and 13 C NMR spectra, HPLC chromatograms, additional NMR data, and figures related to stability studies.

References

- [1] R.F. Barth, J.A. Coderre, M. Vicente, T.E. Blue, Boron neutron capture therapy of cancer: current status and future prospects, *Clin. Cancer Res.* 11 (2005) 3987–4002.
- [2] R.F. Barth, W. Yang, A.S. Al-Madhoun, J. Johnsamuel, Y. Byun, S. Chandra, D.R. Smith, W. Tjarks, S. Eriksson, Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors, *Cancer Res.* 64 (2004) 6287–6295.
- [3] R.F. Barth, W. Yang, G. Wu, M. Swindall, Y. Byun, S. Narayanasamy, W. Tjarks, K. Tordoff, M.L. Moeschberger, S. Eriksson, P.J. Binns, K.J. Riley, Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors, *Proc. Nat. Acad. Sci. U. S. A.* 105 (2008) 17493–17497.
- [4] A.S. Al-Madhoun, J. Johnsamuel, R.F. Barth, W. Tjarks, S. Eriksson, Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy, *Cancer Res.* 64 (2004) 6280–6286.
- [5] W. Tjarks, R. Tiwari, Y. Byun, S. Narayanasamy, R.F. Barth, Carboranyl thymidine analogues for neutron capture therapy, *Chem. Commun.* 47 (2007) 4978–4991.
- [6] E.S. Arner, S. Eriksson, Mammalian deoxyribonuclease kinases, *Pharmacol. Ther.* 67 (1995) 155–186.
- [7] S.E. Aspland, C. Ballatore, R. Castillo, J. Desharnais, T. Eustaquio, P. Golet, Z. Guo, Q. Li, D. Nelson, C. Sun, A.J. Castellino, M.J. Newman, Kinase-mediated trapping of bi-functional conjugates of paclitaxel or vinblastine with thymidine in cancer cells, *Bioorg. Med. Chem. Lett.* 16 (2006) 5194–5198.
- [8] R.B. Silverman, *The Organic Chemistry of Drug Design and Drug Action*, second ed., Elsevier Academic Press, San Diego, 2004.
- [9] A.S. Al-Madhoun, W. Tjarks, S. Eriksson, The role of thymidine kinases in the activation of pyrimidine nucleoside analogues, *Mini-Rev. Med. Chem.* 4 (2004) 341–350.
- [10] H. Davson, M.B. Segal, *Physiology of the CSF and Blood-Brain Barriers*, CRC Press, Boca Raton, 1996.
- [11] F.P. Bonina, L. Arenare, F. Palagiano, A. Saija, F. Nava, D. Trombetta, P.D. Caprariis, Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs, *J. Pharm. Sci.* 88 (1999) 561–567.
- [12] D.B. Williams, S.A. Varia, V.J. Stella, I.H. Pitman, Evaluation of the prodrug potential of the sulfate esters of acetaminophen and 3-hydroxymethylphenytoin, *Int. J. Pharm.* 14 (1983) 113–120.
- [13] G.L. Flynn, D.J. Lamb, Factors influencing solvolysis of corticosteroid-21-phosphate esters, *J. Pharm. Sci.* 59 (1970) 1433–1438.
- [14] H. Bundgaard, C. Larsen, P. Thorbek, Prodrugs as drug delivery systems XXVI. Preparation and enzymatic hydrolysis of various water-soluble amino acid esters of metronidazole, *Int. J. Pharm.* 18 (1984) 67–77.
- [15] X. Song, P.L. Lorenzi, C.P. Landowski, B.S. Vig, J.M. Hilfinger, G.L. Amidon, Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport, *Mol. Pharm.* 2 (2005) 157–167.
- [16] Y. Tsume, B.S. Vig, J. Sun, C.P. Landowski, J.M. Hilfinger, C. Ramachandran, G.L. Amidon, Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters, *Molecules* 13 (2008) 1441–1454.
- [17] B.S. Vig, P.J. Lorenzi, S. Mittal, C.P. Landowski, H. Shin, H.I. Mosberg, J.M. Hilfinger, G.L. Amidon, Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis, *Pharm. Res.* 20 (2003) 1381–1388.
- [18] Y. Sun, J. Sun, S.Y. Jing, S. Yin, Y. Chen, G. Li, Y. Xu, Z. He, Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1- β -D-arabinofuranosylcytosine, *Mol. Pharm.* 6 (2009) 315–325.
- [19] B. Anand, S. Katragadda, Y. Nashed, A. Mitra, Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium, *Curr. Eye Res.* 29 (2004) 153–166.
- [20] S. Katragadda, R. Jain, D. Kwatra, S. Hariharan, A. Mitra, Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells, *Int. J. Pharm.* 362 (2008) 93–101.
- [21] L.M. Beauchamp, G.F. Orr, P. De Miranda, T. Burnette, T.A. Krenitsky, Amino acid ester prodrugs of acyclovir, *Antivir. Chem. Chemother.* 3 (1992) 157–164.
- [22] A.J. Lunato, J. Wang, J.E. Woollard, A.K.M. Anisuzzaman, W. Ji, F.G. Rong, S. Ikeda, A.H. Soloway, S. Eriksson, D.H. Ives, T.E. Blue, W. Tjarks, Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl) thymidines and their evaluation as substrates for human thymidine kinases 1 and 2, *J. Med. Chem.* 42 (1999) 3378–3389.
- [23] R. Tiwari, A. Toppino, H.K. Agarwal, T. Huo, Y. Byun, J. Gallucci, S. Hasabelnaby, A. Khalil, A. Goudah, R.A. Baiocchi, M.V. Darby, R.F. Barth, W. Tjarks, Synthesis, biological evaluation, and radioiodination of halogenated *closo*-carboranylthymidine analogues, *Inorg. Chem.* 51 (2012) 629–639.
- [24] F.A. Gomez, M.F. Hawthorne, A simple route to C-monosubstituted carborane derivatives, *J. Org. Chem.* 5 (1992) 1384–1390.
- [25] Y. Byun, B.T.S. Thirumamagal, W. Yang, S. Eriksson, R.F. Barth, W. Tjarks, Preparation and biological evaluation of 10 B-enriched 3-[5-(2-(2,3-dihydroxyprop-1-yl)-*o*-carboran-1-yl)pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors, *J. Med. Chem.* 49 (2006) 5513–5523.
- [26] L. Colla, E. De Clercq, R. Busson, H. Vanderhaeghe, Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl] guanine], *J. Med. Chem.* 26 (1983) 602–604.
- [27] A.E. Thomsen, G.M. Friedrichsen, A.H. Sørensen, R. Andersen, C.U. Nielsen, B. Brodin, M. Begtrup, S. Frokjaer, B. Steffansen, Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism, *J. Control. Release* 86 (2003) 279–292.
- [28] N.J. Abbott, Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology, *Neurochem. Int.* 45 (2004) 545–552.
- [29] C.P. Landowski, P.L. Lorenzi, X. Song, G.L. Amidon, Nucleoside ester prodrug substrate specificity of liver carboxylesterase, *J. Pharmacol. Exp. Ther.* 316 (2006) 572–580.
- [30] M. Nedergaard, T. Takano, A.J. Hansen, Beyond the role of glutamate as a neurotransmitter, *Nat. Rev. Neurosci.* 3 (2002) 748–755.
- [31] K. Yamamoto, Y. Endo, Bioorg. Utility of boron clusters for drug design. Hansch-fujita hydrophobic parameters π of dicarba-*closo*-dodecaboranyl groups, *Med. Chem. Lett.* 11 (2001) 2389–2392.
- [32] B.T.S. Thirumamagal, X.B. Zhao, A.K. Bandyopadhyaya, J. Johnsamuel, R. Tiwari, D.W. Golightly, V. Patel, B.T. Jehning, M.V. Backer, R.F. Barth, R.J. Lee, J.M. Backer, W. Tjarks, Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT), *Bioconjug. Chem.* 17 (2006) 1141–1150.
- [33] J.L. Fauchere, K. Quang Do, P.Y.C. Jow, C. Hansch, Unusually strong lipophilicity of 'fat' or 'super' amino-acids, including a new reference value for glycine, *Experientia* 36 (1980) 1203–1204.
- [34] S. Narayanasamy, B.T.S. Thirumamagal, J. Johnsamuel, Y. Byun, A.S. Al-Madhoun, E. Usova, G.Y. Cosquer, J. Yan, A.K. Bandyopadhyaya, R. Tiwari, S. Eriksson, W. Tjarks, Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer, *Bioorg. Med. Chem.* 14 (2006) 6886–6899.
- [35] T.L. Lemke, D.A. Williams, Foye's Principles of Medicinal Chemistry, sixth ed., Lippincott Williams & Wilkins, Philadelphia, 2007.
- [36] G.E. Granero, G.L. Amidon, Stability of valacyclovir: Implications for its oral bioavailability, *Int. J. Pharm.* 317 (2006) 14–18.